RT Journal Article
SR Electronic
T1 Testing for <em>BRAF</em> fusions in patients with advanced <em>BRAF</em>/<em>NRAS</em>/<em>KIT</em> wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 116
OP 119
DO 10.1136/jclinpath-2019-206026
VO 73
IS 2
A1 Le Flahec, Glen
A1 Briolais, Manon
A1 Guibourg, Briac
A1 Lemasson, Gilles
A1 Grippari, Jean-Luc
A1 Ledé, Francoise
A1 Marcorelles, Pascale
A1 Uguen, Arnaud
YR 2020
UL http://jcp.bmj.com/content/73/2/116.abstract
AB Beyond targeted therapy for patients with BRAF-mutated melanomas and immunotherapy in patients lacking BRAF mutations, anti-MEK therapy has been proposed in patients with advanced melanomas harbouring BRAF fusions. BRAF fusions diagnosis in patients with advanced melanomas is the subject of the present study. Using BRAF fluorescent in situ hybridisation (FISH), we searched for BRAF fusions in 74 samples of 66 patients with advanced BRAF/NRAS/KIT wild-type melanomas. We identified 2/66 (3%) patients with BRAF fusions in a brain metastasis of one patient and in a lymph node metastasis and in a cutaneous metastasis for the second patient with 90%–95% of tumour nuclei containing isolated 3′-BRAF FISH signals. As a result, we conclude that BRAF FISH in patients with advanced BRAF/NRAS/KIT wild-type melanomas is a valuable and easy-to-perform test to diagnose BRAF fusions and to identify patients who could benefit of anti-MEK targeted therapy.